Dr. Falk Pharma GmbH vs. Ellodi Pharmaceuticals LP
Explore the PTAB proceeding IPR2025-00052 filed by Dr. Falk Pharma GmbH on 2024-10-24. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.
Proceeding Overview
Proceeding Number
IPR2025-00052
Filing Date
2024-10-24
Accorded Filing Date
2024-10-24
Institution Decision Date
2025-06-03
Last Modified Date
2026-03-30
Proceeding Type
IPR
Termination Date
2026-01-23
Trial Status
Terminated-Adverse Judgment
Parties & Counsel
Petitioner
Dr. Falk Pharma GmbH
Represented By
Luman, Nathanaelet alPatent Owner / Respondent
Ellodi Pharmaceuticals LP
Represented By
Sukduang, Sanyaet alPatent Information
Tribunal & APJ Panel Intelligence
Tribunal
Patent Trial and Appeal Board (USPTO)
Technology Center
TC 1600 - Biotechnology & Organic Chemistry
Decisions Rendered
2 Total
Proceeding Status
Terminated-Adverse Judgment
Administrative Patent Judges (APJ Panel)
Board Decisions & Rulings (2)
Address and Attorney/Agent Information
Power of Attorney & Correspondence
Attorney / Agent Information
| Reg # | Name | Phone |
|---|---|---|
| 33885 | William Galliani | +1 650-843-5622 |
| 34262 | C Talbot | +1 703-456-8072 |
| 36343 | Matthew Langer | +1 212-497-6000 |
| 40673 | Heidi Keefe | +1 650-843-5000 |
| 41087 | Christopher Hutter | +1 703-456-8506 |
| 42669 | Brian Hopkins | +1 617-937-2300 |
| 42764 | Cynthia Kozakiewicz | +1 617-937-2300 |
| 43210 | Michael Tuscan | +1 202-842-7802 |
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 10 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 10,632,069 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,246,828 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 11,266,598 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 12,290,598 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2026002104 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2026008366 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 24,764,209 P | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 8,771,729 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 9,387,167 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 9,849,084 B2 | US Continuation / Sibling | View Official Patent → |
Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals
Dr. Falk Pharma GMBH v. Ellodi Pharmaceuticals LP
DR. FALK PHARMA GMBH v. Ellodi Pharmaceuticals LP